Brussels, 07/08/2001 (Agence Europe) - For the first time, two orphan medicinal products (i.e., intended to treat rare diseases) have received the Commission's approval to be placed on the market in the European Union. These are Fabrazyme and Replagal, two medicines containing the active substance a-Galactosidase, and intended to treat patients affected by Fabry's disease, rare and hereditary genetic disease affecting one person in 400,000 in the Union.
The two medicines were perfected by...